ONCE - Spark Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
47.76
-2.11 (-4.23%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close49.87
Open49.87
Bid47.65 x 2900
Ask51.37 x 1300
Day's Range47.38 - 51.12
52 Week Range41.06 - 96.59
Volume315,001
Avg. Volume656,018
Market Cap1.794B
Beta (3Y Monthly)2.00
PE Ratio (TTM)N/A
EPS (TTM)-2.56
Earnings DateAug 8, 2017 - Aug 14, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est69.68
Trade prices are not sourced from all markets
  • See what the IHS Markit Score report has to say about Spark Therapeutics Inc.
    Markit18 hours ago

    See what the IHS Markit Score report has to say about Spark Therapeutics Inc.

    Spark Therapeutics Inc NASDAQ/NGS:ONCE

  • GlobeNewswire3 days ago

    Detailed Research: Economic Perspectives on Cerus, AdvanSix, Spark Therapeutics, Imperva, Central Garden & Pet, and Francesca's — What Drives Growth in Today's Competitive Landscape

    NEW YORK, Oct. 18, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Spark Therapeutics to add up to 500 jobs in West Philadelphia expansion
    American City Business Journals10 days ago

    Spark Therapeutics to add up to 500 jobs in West Philadelphia expansion

    Spark Therapeutics Inc. said Thursday it is expanding its research-and-development operations in West Philadelphia in a move expected to create nearly 500 high-paying jobs. The gene therapy company spun out of Children's Hospital of Philadelphia is getting a $2 million Department of Community and Economic Development grant and a $7.5 million grant from the Redevelopment Assistance Capital Program to support the project. Spark's new site will be located on Market Street in Drexel University’s $3 billion Schuylkill Yards development project.

  • GlobeNewswire13 days ago

    Spark Therapeutics Announces New Preclinical Data for Pompe Disease Gene Therapy Candidate

    Spark Therapeutics (ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, today announced new data for SPK-3006, an investigational liver-directed adeno-associated viral (AAV) gene therapy for Pompe disease. The data from the Investigational New Drug (IND)-enabling studies were presented Saturday, Oct. 6, 2018, in an oral presentation, “Safety and efficacy evaluation of investigational liver gene transfer for secretable GAA in the treatment of Pompe disease,” during the Late Breaking Session at the 23rd International Congress of the World Muscle Society in Argentina.

  • With Hemlibra, Roche seeks to break into tight hemophilia circle
    Reuters18 days ago

    With Hemlibra, Roche seeks to break into tight hemophilia circle

    Swiss drugmaker Roche (ROG.S) is breaking into hemophilia A treatment, a $10 billion (£7.70 billion) global market dominated by rivals who have cultivated close ties to sufferers of the genetic bleeding disorder. Roche's Hemlibra, on sale since late 2017 for patients with resistance to existing treatments, is widely expected to win the U.S. Food and Drug Administration's blessing for use in nearly all patients this week. To hit $5 billion global annual sales that some analysts forecast, Hemlibra must wrest business away from hemophilia giants like Shire (SHP.L), Bayer (BAYGn.DE), Novo Nordisk (NOVOb.CO) and Octapharma, whose "clotting factors" are now standard for people who lack proteins that stop bleeding.

  • An Investor’s Overview of Spark Therapeutics
    Market Realist22 days ago

    An Investor’s Overview of Spark Therapeutics

    Spark Therapeutics (ONCE) stock closed at $54.85 yesterday, ~76% below its 52-week high of $96.59 on July 9. Spark Therapeutics stock has fallen 12% from $61.61 on August 31. Its 52-week low is $41.06, which it reached on December 11, 2017.

  • Where Philadelphia ranks among the top biotech clusters
    American City Business Journals23 days ago

    Where Philadelphia ranks among the top biotech clusters

    The region attracted $772.79 million in 22 venture capital deals deals during the past 18 months, according to the biotech clusters report.

  • The Wall Street Journal26 days ago

    High Hopes for a Gene Therapy Come With Fears Over Cost

    Caspian was born with a rare, inherited eye disorder called Leber congenital amaurosis, which results in the progressive deterioration of the retina, the tissue at the back of the eye that detects light and color. This month Caspian became among the first patients in the country to receive a new gene-therapy treatment called Luxturna, which his doctors at Oregon Health & Science University believe will improve his vision and prevent further deterioration. The therapy entails inserting a functional gene through harmless, virus-like particles into the retinal cells to compensate for the faulty gene causing his disease.

  • Novartis Gets Positive CHMP Opinion for Drugs, Biosimilar
    Zacks26 days ago

    Novartis Gets Positive CHMP Opinion for Drugs, Biosimilar

    Novartis (NVS) gets positive CHMP opinion for a label expansion of Gilenya, gene therapy, and a biosimilar of Neulasta.

  • The Wall Street Journallast month

    [$$] Triple Set of EMA Recommendations for Novartis Drugs

    AG (NOVN.EB) drugs and one Sandoz biosimilar have received a positive European Medicines Agency recommendation, the company and the regulator said in separate statements Friday. Novartis’ Gilenya, a multiple-sclerosis drug, received a positive recommendation for the treatment of children and adolescents with the condition. If approved, the drug would be the first oral disease-modifying therapy for these patients, Novartis said, adding that a full approval would expand the age-range of patients able to use the drug.

  • Reuterslast month

    Spark's Luxturna blindness therapy gets European panel nod

    A European Medicines Agency panel recommended approval of Spark Therapeutics' gene therapy for blindness, a move that also boosts Swiss drugmaker Novartis that bought the rights to one of the world's costliest treatments outside the United States. The Committee for Medicinal Products for Human Use (CHMP) recommended http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2018/09/news_detail_003025.jsp&mid=WC0b01ac058004d5c1 voretigene neparvovec, approved as Luxturna in the United States, for patients suffering from inherited retinal dystrophy caused by RPE65 gene mutations, a rare genetic disorder that causes vision loss and usually leads to blindness.

  • GlobeNewswirelast month

    Spark Therapeutics Announces Positive CHMP Opinion for One-time Gene Therapy LUXTURNA® (voretigene neparvovec) in the European Union

    Spark Therapeutics (ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending approval of LUXTURNA® (voretigene neparvovec), a one-time gene therapy for the treatment of adult and pediatric patients with vision loss due to inherited retinal dystrophy caused by confirmed biallelic RPE65 mutations and who have sufficient viable retinal cells. “We are encouraged by today’s decision, which further affirms our pioneering clinical program and brings LUXTURNA one step closer to patients with inherited retinal disease (IRD) caused by mutations in both copies of the RPE65 gene in the European Union,” said Katherine A. High, M.D., president and head of research & development at Spark Therapeutics.

  • See what the IHS Markit Score report has to say about Spark Therapeutics Inc.
    Markitlast month

    See what the IHS Markit Score report has to say about Spark Therapeutics Inc.

    Spark Therapeutics Inc NASDAQ/NGS:ONCE

  • Markitlast month

    See what the IHS Markit Score report has to say about Spark Therapeutics Inc.

    Spark Therapeutics Inc NASDAQ/NGS:ONCE

  • What Spark Therapeutics’ Valuation Trend Indicates
    Market Realistlast month

    What Spark Therapeutics’ Valuation Trend Indicates

    Of the 22 analysts covering Spark Therapeutics in September, 11 of them have recommended a “buy” or higher, and nine have recommended a “hold.” Two analysts have given the stock a “sell” or lower rating. The mean rating for Spark stock is 2.41 with a target price of $69.67, implying an upside potential of 18% over its closing price of $59.04 on September 13. Its peers Esperion Therapeutics (ESPR), Intercept Pharmaceuticals (ICPT), and Axovant Sciences (AXON) have mean ratings of 2.27, 2.41, and 2.71, respectively, and target prices of $72.68, $123.07, and $4.70, respectively.

  • How Spark Therapeutics Is Positioned in 2018
    Market Realistlast month

    How Spark Therapeutics Is Positioned in 2018

    Spark Therapeutics (ONCE) is a gene therapy company focused on developing one-time treatments that are life-altering for genetic disease patients. Spark Therapeutics has a licensing and commercialization agreement with Novartis (NVS) for its investigational voretigene neparvovec. Spark Therapeutics has two gene therapy product candidates in its pipeline: SPK-7001 and SPK-8011.

  • BioMarin Pharmaceutical and Its Promising Research Pipeline
    Market Realistlast month

    BioMarin Pharmaceutical and Its Promising Research Pipeline

    Stocks focused on gene therapy have garnered strong investor interest in 2018. While some of them have been climbing steadily, others have received strong price corrections on pipeline news. In this series, we’ll analyze four companies: BioMarin Pharmaceutical (BMRN), Solid Biosciences (SLDB), Spark Therapeutics (ONCE), and uniQure (QURE).

  • Analysts Are Mostly Positive on Intellia Therapeutics This Month
    Market Realistlast month

    Analysts Are Mostly Positive on Intellia Therapeutics This Month

    Intellia Therapeutics is a genome-editing company that’s currently focused on the development of curative therapies utilizing the CRISPR/Cas9 system. In August, Intellia Therapeutics presented data from a study in which a humanized mouse model of hereditary transthyretin amyloidosis demonstrated a reduction in amyloid deposition in multiple tissues after the administration of a single dose of lipid nanoparticles. Of the seven analysts tracking Intellia Therapeutics in September, three have recommended “strong buys,” while three have recommended “buys” on its stock.

  • Exelixis’s Cabometyx Receives New Treatment Recommendations
    Market Realistlast month

    Exelixis’s Cabometyx Receives New Treatment Recommendations

    Today, Exelixis announced that the NCCN (National Comprehensive Cancer Network) had updated its clinical practice guidelines, in which it recommended Cabometyx tablets for the treatment of individuals with advanced renal cell carcinoma irrespective of the patient’s risk status. The NCCN’s clinical practice guidelines for kidney cancer now recommend Cabometyx as the only preferred TKI (tyrosine kinase inhibitor) therapy in treatment-naïve patients who are in the poor to intermediate risk group.

  • 5 Healthcare Stocks That Are Down, But Not Out!
    InvestorPlace2 months ago

    5 Healthcare Stocks That Are Down, But Not Out!

    Few investment sectors arouse sharply divided opinion quite like healthcare stocks. This segment features incredible volatility as poor clinical trials could devastate individual companies. During the campaign trail for the 2016 presidential election, then-real-estate-mogul Donald Trump lashed out against pharmaceuticals.

  • GlobeNewswire2 months ago

    Report: Exploring Fundamental Drivers Behind Fiesta Restaurant Group, Emerge Energy Services LP, Collegium Pharmaceutical, Cutera, Resources Connection, and Spark Therapeutics — New Horizons, Emerging Trends, and Upcoming Developments

    NEW YORK, Aug. 24, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Fiesta ...

  • See what the IHS Markit Score report has to say about Spark Therapeutics Inc.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Spark Therapeutics Inc.

    Spark Therapeutics Inc NASDAQ/NGS:ONCE

  • The Cost of Cures: How Investing in Biotech Stocks Could Soon Be Radically Changed
    Motley Fool2 months ago

    The Cost of Cures: How Investing in Biotech Stocks Could Soon Be Radically Changed

    Get ready for a golden age of medicine that could dramatically shake up which biotechs get the gold.

  • Motley Fool2 months ago

    Is Spark Therapeutics a Bad News Buy?

    The company’s latest trial data failed to ignite a rally in its share price.